Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have shown that a combination of treatments can improve the effectiveness of immunotherapy in lung cancer. The study, published today in Nature Communications, indicates that simultaneous targeting of tumors using multiple treatment modalities could improve treatment response, particularly in…

In an advance for AI in drug discovery, SOPHiA GENETICS, in collaboration with AstraZeneca, recently presented data generated using multimodal machine learning models to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from a specific treatment—the addition of tremelimumab to durvalumab and chemotherapy.…

A survey by the International Association for the Study of Lung Cancer (IASLC) has shown that although lung cancer biomarker testing rates have increased substantially since 2018, they remain suboptimal, particularly for patients with early-stage disease. Cost, time, sample quality, access to testing, and a lack of awareness were the…

Originally Aired: September 19, 2024Time: 8:00 am PT, 11:00 am ET, 17:00 CET VIEW NOW Early diagnosis and swift treatment are critical to changing the lung cancer landscape. Aligned with this goal, blood-based testing is a valuable tool to support clinical decision-making from diagnosis through monitoring. In this webinar, Dr. Gary Pestano…

A lung cancer patient at University College London Hospitals (UCLH) was the first to receive a novel mRNA-based vaccine designed to prime the immune system to fight cancer cells very specifically. The BioNTech immunotherapy (BNT116) is being studied in a worldwide lung cancer trial. The NIHR UCLH Clinical Research Facility…

Lung cancer screening (LCS) is a crucial tool in the early detection and treatment of lung cancer. However, according to a new study in the Annals of Internal Medicine, current eligibility criteria may be excluding many individuals who could benefit most from screening. The study proposes a new set of…

New research from the Brigham and Women’s Hospital investigators has provided new details on different levels of cardiac risks for patient who receive radiation therapy to treat non-small cell lung cancer (NSCLC). The study, published in JACC: CardioOncology, leveraged artificial intelligence (AI) to uncover how different radiation doses impact specific…

AstraZeneca (AZ) announced Thursday that its supplemental Biologic License Application has been granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of limited-stage small cell lung cancer (LS-SCLC). The regulatory decision is based on results of the ADRIATIC Phase III clinical trial in patients with…

A new article in the Journal of Thoracic Oncology argues that the current evidence is insufficient to support lung cancer screening for individuals who have never smoked, even if they have a family history of lung cancer. The piece highlights the complexities involved in public health policy regarding cancer screening.…

Lung adenocarcinoma is the most common form of lung cancer in the world, and genetic markers are needed to help predict the prognosis of this disease and improve treatment outcomes. Using gene databases and patient data, a team from the Tongji Medical School and the Huazhong University of Science and…

University of Illinois researchers have identified a link between high levels of neighborhood violence and lung cancer progression that may partially explain disparities in lung cancer outcomes between Black men and White men. Writing in Cancer Research Communications, study co-lead Zeynep Madak-Erdogan, a food science and human nutrition professor at…

Targeted treatment for non-small cell lung cancer (NSCLC) sometimes fails to work, even in patients who have never smoked. The reason, new research suggests, hangs on two mutations in the EGFR and TP53 genes. Patients with mutations in these two genes are more likely to have mixed intra-patient tumor responses…

Scientists have engineered algae-based microrobots capable of swimming through the lungs to deliver chemotherapy directly to the lungs. In mouse models of melanoma, the treated mice reduced tumor growth and spread and improved survival. The findings are detailed in a paper published on June 12 in Science Advances. The microrobots were…

A self-taught artificial intelligence system can identify a common form of lung cancer from microscopy images and determine the likelihood that it will return after treatment as well as overall patient survival. The system has potential to one day relieve pathologists from the time-consuming manual interpretation of stained tissue sections.…

LORBRENA (Pfizer’s lorlatinib) has delivered the longest progression-free survival (PFS) ever reported in advanced ALK-positive, non–small cell lung cancer (NSCLC). The company reported 60% of patients treated with LORBRENA were alive without disease progression after five years, according to data from the phase III CROWN trial data presented during the…